Desamparados Roda

Desamparados Roda

Auto-generated profile, based on publicly available information

Desamparados Roda

Biomedical Research Institute INCLIVA, Valencia, Spain

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2022 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
RJRobert Jones
Robert Jones
RPRuth Plummer
Ruth Plummer
Victor MorenoVictor Moreno
Victor Moreno
LCLouise Carter
Louise Carter
DRDesamparados Roda
Desamparados Roda
UBUdai Banerji
Udai Banerji
Purpose: This was a Phase I/II trial of the novel checkpoint kinase 1 (Chk1) inhibitor SRA737 given in combination with gemcitabine. Its objectives were to establish the safety profile, recommended Phase 2 dose (RP2D), pharmacokinetics profile, and clinical activity of SRA737. Patients and Methods: Patients with advanced solid tumors were enrolled into dose-escalation cohorts and treated in 28-day cycles with oral SRA737 on days 2, 3, 9, 10, 16, and 17, and intravenous gemcitabine on days 1, 8, and 15. Treatment was continued until progression. Each expansion cohort included up to 20 patients with specific genetically defined tumors. Results: The RP2D was determined to be 500 mg SRA737 combined with low-dose (250 mg/m2) gemcitabine. Of 143 enrolled patients, 77 were treated at doses of at least 500 mg SRA737 combined with 250 mg/m2 gemcitabine. Common toxicities of nausea, vomiting, fatigue, and diarrhea were primarily mild to moderate, and rarely led to treatment discontinuation. Anemia, neutropenia, and thrombocytopenia were grade ≥3 in 11.7%, 16.7%, and 10% of patients treated at the RP2D, respectively. The objective response rate (ORR) was 10.8% overall and notably the ORR in anogenital cancer was 25%. Partial tumor responses were observed in anogenital cancer, cervical cancer, high-grade serous ovarian cancer, rectal cancer, and small cell lung cancer. Conclusions: SRA737 in combination with low-dose gemcitabine was well tolerated with lower myelotoxicity than has been seen at standard doses of gemcitabine or with other combinations of Chk1 inhibitors with gemcitabine. Tumor responses were observed in anogenital and other solid tumors.

20 January 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
THTenna V Henriksen
Tenna V Henriksen
NTNoelia Tarazona
Noelia Tarazona
TRThomas Reinert
Thomas Reinert
JCJuan Antonio Carbonell-Asins
Juan Antonio Carbonell-Asins
DRDerrick Renner
Derrick Renner
CAClaus Lindbjerg Andersen
Claus Lindbjerg Andersen
11Background: Timely detection of recurrence, as well as identification of patients at high risk of recurrence after surgery and after completion of adjuvant therapy, are major challenges in the tr...

3 July 2021 in Cancer Immunology, Immunotherapy
Verified
Journal Article
Open access
PDF file
ANTOINE ITALIANOANTOINE ITALIANO
ANTOINE ITALIANO
PCPhilippe A. Cassier
Philippe A. Cassier
CLChia-Chi Lin
Chia-Chi Lin
TATuomo Alanko
Tuomo Alanko
KPKatriina J. Peltola
Katriina J. Peltola
Victor MorenoVictor Moreno
Victor Moreno
Background: Budigalimab is a humanized, recombinant immunoglobulin G1 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We present the safety, efficacy, pharmacokinetic (PK), and pharmacodynamic data from patients enrolled in the head and neck squamous cell carcinoma (HNSCC) and non-small cell lung cancer (NSCLC) expansion cohorts of the phase 1 first-in-human study of budigalimab monotherapy (NCT03000257; registered 15 December 2016). Patients and methods: Patients with recurrent/metastatic HNSCC or locally advanced/metastatic NSCLC naive to PD-1/PD-1-ligand inhibitors were enrolled; patients were not selected on the basis of oncogene driver mutations or PD-L1 status. Budigalimab was administered at 250 mg intravenously Q2W or 500 mg intravenously Q4W until disease progression/unacceptable toxicity. The primary endpoints were safety and PK; the secondary endpoint was efficacy. Exploratory endpoints included biomarker assessments. Results: In total, 81 patients were enrolled (HNSCC: N = 41 [PD-L1 positive: n = 19]; NSCLC: N = 40 [PD-L1 positive: n = 16]); median treatment duration was 72 days (range, 1–617) and 71 days (range, 1–490) for the HNSCC and NSCLC cohorts, respectively. The most frequent grade ≥ 3 treatment-emergent adverse event was anemia (HNSCC: n = 9, 22%; NSCLC: n = 5, 13%). Both dosing regimens had comparable drug exposure and increased interferon gamma-induced chemokines, monokine induced by gamma interferon, and interferon-gamma-inducible protein 10. Objective response rates were 13% (90% CI, 5.1–24.5) in the HNSCC cohort and 19% (90% CI, 9.2–32.6) in the NSCLC cohort. Median progression-free survival was 3.6 months (95% CI, 1.7–4.7) and 1.9 months (95% CI, 1.7–3.7) in the HNSCC and NSCLC cohorts. Conclusions: The safety, efficacy and biomarker profiles of budigalimab are similar to other PD-1 inhibitors. Development of budigalimab in combination with novel anticancer agents is ongoing.

1 May 2020 in Annals of Oncology
Verified
Journal Article
Closed access
PDF file
POP. Tolosa Ortega
P. Tolosa Ortega
JCJuan M Cejalvo
Juan M Cejalvo
STS. Moragon Terencio
S. Moragon Terencio
LCL. Carril-Ajuria
L. Carril-Ajuria
BBB. Bermejo
B. Bermejo
LML. Manso
L. Manso